Loading organizations...
Mate Fertility builds and operates tech-enabled fertility clinics, offering a streamlined platform that delivers affordable and accessible fertility services. The company's core approach focuses on connecting patients with providers, addressing longstanding inefficiencies within the fertility care industry. They integrate technology to simplify the overall treatment process, aiming to make the path to parenthood less complicated and more cost-effective for a broader demographic.
The company was founded by brothers Gabriel Bogner and Oliver Bogner, driven by their personal experiences and deep understanding of the challenges surrounding in vitro fertilization. Their insight highlighted the need for a more accessible and people-centered approach to fertility care. Starting around 2023, the Bogner brothers aimed to disrupt traditional models by bringing high-quality treatment to a wider audience, moving beyond existing barriers in the sector.
Mate Fertility primarily serves individuals and couples navigating fertility journeys, with a particular emphasis on reaching underserved communities who historically face significant hurdles to access care. The company’s overarching vision is to democratize fertility services, ensuring that the critical path to parenthood is not limited by prohibitive costs or complex systems. They aspire to transform the industry by making comprehensive fertility care universally attainable.
Mate Fertility has raised $3.0M across 1 funding round.
Mate Fertility has raised $3.0M in total across 1 funding round.
Mate Fertility has raised $3.0M in total across 1 funding round.
Mate Fertility's investors include Austin Ventures, Basecamp Fund, Founder Collective, Grace Beauty Capital, Kaya Ventures, KittyHawk Ventures, Monarch Collective, Next Coast Ventures, Ravelin Capital, Red Swan Ventures, S3 Ventures, Science.
Mate Fertility has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in December 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2020 | $3M Seed | — | Austin Ventures, Basecamp Fund, Founder Collective, Grace Beauty Capital, Kaya Ventures, KittyHawk Ventures, Monarch Collective, Next Coast Ventures, Ravelin Capital, RED Swan Ventures, S3 Ventures, Science, SoftBank Investment Advisers, Spacecadet Ventures, Springdale Ventures, Starther, Brian Cruver, Dave Balter, Ethan Austin, IAN Lopatin, Jiake LIU, Mark Cuban, Suhail Doshi, Thomas VU, TOM Mcinerney, Vince Thompson | Announced |
Mate Fertility is a healthcare startup that builds a "fertility clinic in a box" model, enabling OB/GYN practices in underserved U.S. areas to offer affordable, high-quality IVF and fertility services like egg freezing, surrogacy, genetic screening, and at-home hormone testing.[2][3][4][5] It serves prospective parents facing infertility—one in eight couples—by partnering with local providers, upskilling them under reproductive endocrinologist (REI) supervision, and delivering 30-40% lower costs with pregnancy rates 20-22% above the national average.[2][3][6] With three operational locations and $971,624 in 2022 revenue, the company has raised over $7M in seed and Series A funding, showing strong growth momentum toward national expansion.[2][3][4][6]
Founded in 2021 in Los Angeles by brothers Gabriel Bogner (from venture background) and Oliver Bogner, Mate Fertility emerged from frustration with high-cost, urban-centric IVF clinics often owned by private equity, which exploit vulnerable patients in "fertility deserts."[2][4][8] Partnering early with Dr. Jeffrey Steinberg, an endocrinologist trained by IVF pioneers, they aimed to decentralize care to rural and suburban OB/GYN offices.[4] Traci Keen joined as an early hire, rising to CEO for her execution skills; she highlights the model's roots in addressing a societal infertility surge unmet by 1970s-80s clinic infrastructure.[3][6] Pivotal early traction included launching three clinics with superior outcomes, securing $2.8M seed from Struck Capital, and a $4.2M Series A in 2023.[2][3][4][6]
Mate Fertility rides the rising infertility crisis (one in eight couples affected) amid delayed parenthood, clinician shortages, and geographic barriers, scaling supply via OB/GYN decentralization in a private equity-consolidated market.[2][3][4][6] Timing aligns with femtech boom and at-home diagnostics, positioning Mate to meet unmet demand in "fertility deserts" where travel and costs block care.[1][3][5] Favorable forces include tech efficiencies (EHR/portals) lowering overhead and partnerships like Innovative Health Diagnostics expanding at-home testing, influencing ecosystem by upskilling providers and proving "clinic-in-a-box" for broken specialties.[3][4][5][6]
Mate Fertility's playbook—tech-enabled partnerships yielding better outcomes at lower costs—positions it to dominate U.S. fertility access, potentially hitting dozens of clinics soon via ongoing Series A and crowdfunding.[3][6] Trends like at-home testing, payer coverage growth, and model adaptability to other care areas (e.g., oncology) will accelerate expansion, evolving its influence from niche disruptor to systemic fixer in fragmented healthcare.[3][5] As infertility demand surges, Mate could redefine equitable family-building, fulfilling its founding vision of affordability for all.
